相似文献
1
Ethical Concerns about Psilocybin Intellectual Property.
ACS Pharmacol Transl Sci. 2021 Jan 1;4(2):573-577. doi: 10.1021/acsptsci.0c00171. eCollection 2021 Apr 9.
2
[Levels of psilocybin and psilocin in various types of mushrooms].
Soud Lek. 2003 Jul;48(3):45-9.
3
Intangible cultural heritage: a benefit to climate-displaced and host communities.
J Environ Stud Sci. 2021;11(3):305-315. doi: 10.1007/s13412-021-00697-y. Epub 2021 May 8.
4
[Status and prospect of protection of intangible cultural heritage-traditional medicine in the international social community].
Zhonghua Yi Shi Za Zhi. 2011 Mar;41(2):79-83.
5
DARK Classics in Chemical Neuroscience: Psilocybin.
ACS Chem Neurosci. 2018 Oct 17;9(10):2438-2447. doi: 10.1021/acschemneuro.8b00186. Epub 2018 Jul 16.
6
Iterative l-Tryptophan Methylation in Psilocybe Evolved by Subdomain Duplication.
Chembiochem. 2018 Oct 18;19(20):2160-2166. doi: 10.1002/cbic.201800336. Epub 2018 Oct 2.
7
Magic truffles or Philosopher's stones: a legal way to sell psilocybin?
Drug Test Anal. 2013 Mar;5(3):182-5. doi: 10.1002/dta.1400. Epub 2012 Aug 9.
8
Below the radar innovations and emerging property right approaches in Tibetan medicine.
J World Intellect Prop. 2017 Nov;20(5-6):239-257. doi: 10.1111/jwip.12084. Epub 2017 Nov 7.
9
Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications.
Br J Psychiatry. 1978 Jun;132:602-4. doi: 10.1192/bjp.132.6.602.
10
Intellectual property rights and traditional medicine: policy dilemmas at the interface.
Soc Sci Med. 2003 Aug;57(4):745-56. doi: 10.1016/s0277-9536(02)00425-2.
引用本文的文献
1
Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.
Transl Psychiatry. 2025 Aug 29;15(1):330. doi: 10.1038/s41398-025-03556-4.
2
Towards culturally inclusive healthcare in Peru: Mapping epistemic concepts in contemporary Indigenous Amazonian medicine-Traditional healers' perspectives.
PLOS Glob Public Health. 2025 Jan 17;5(1):e0003912. doi: 10.1371/journal.pgph.0003912. eCollection 2025.
3
The original caretakers of salvinorin A and recognizing Indigenous contributions to science.
Nat Chem. 2024 Nov;16(11):1735-1736. doi: 10.1038/s41557-024-01659-x.
4
Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.
Public Health Ethics. 2024 Mar 1;17(1-2):24-39. doi: 10.1093/phe/phae002. eCollection 2024 Apr-Jul.
5
Traditional Indigenous-Amazonian Therapy Involving Ceremonial Tobacco Drinking as Medicine: A Transdisciplinary Multi-Epistemic Observational Study.
Health Educ Behav. 2024 Dec;51(6):796-808. doi: 10.1177/10901981231213348. Epub 2024 Oct 3.
6
Global species diversity and distribution of the psychedelic fungal genus .
Heliyon. 2023 May 18;9(6):e16338. doi: 10.1016/j.heliyon.2023.e16338. eCollection 2023 Jun.
7
ARC: a framework for access, reciprocity and conduct in psychedelic therapies.
Front Psychol. 2023 May 11;14:1119115. doi: 10.3389/fpsyg.2023.1119115. eCollection 2023.
8
Cognitive liberty and the psychedelic humanities.
Front Psychol. 2023 May 4;14:1128996. doi: 10.3389/fpsyg.2023.1128996. eCollection 2023.
9
Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.
3 Biotech. 2022 Dec;12(12):339. doi: 10.1007/s13205-022-03355-4. Epub 2022 Nov 4.
10
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
Neuropharmacology. 2022 Nov 15;219:109214. doi: 10.1016/j.neuropharm.2022.109214. Epub 2022 Aug 13.
本文引用的文献
1
Economic burden of relapse/recurrence in patients with major depressive disorder.
J Drug Assess. 2019 May 24;8(1):97-103. doi: 10.1080/21556660.2019.1612410. eCollection 2019.
2
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.
3
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
Front Pharmacol. 2018 Jan 17;8:974. doi: 10.3389/fphar.2017.00974. eCollection 2017.
4
Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rights.
J Law Biosci. 2016 Feb 6;3(1):217-226. doi: 10.1093/jlb/lsw003. eCollection 2016 Apr.
Zotero 插件